Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, MD, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault, MD PhD

Blood (2019) 134 (Supplement_1): 1310.

https://doi.org/10.1182/blood-2019-127351

Published: 2019

Journal Articles

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Lakshman Vasanthamohan, MD FRCPC, Brent Parker, MD, Joy Mangel, MD FRCPC, Selay Lam, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Chai Wye Phua, MD FRCPC

Blood (2019) 134 (Supplement_1): 4131.

https://doi.org/10.1182/blood-2019-126997

Published: 2019

Journal Articles

Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Blood (2017) 130 (Supplement 1): 2587.

https://doi.org/10.1182/blood.V130.Suppl_1.2587.2587

Published: 2017

Journal Articles

Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Blood (2015) 126 (23): 3787.

https://doi.org/10.1182/blood.V126.23.3787.3787

Published: 2015

Journal Articles

Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients

Alessia Bari, Luigi Marcheselli, Tamar Tadmor, Raffaella Marcheselli, Maria Christina Cox, MDPhD, Samantha Pozzi, Angela Ferrari, Luca Baldini, Paolo Gobbi, Massimo Federico, Aaron Polliack, Stefano Sacchi

Blood (2015) 126 (23): 3862.

https://doi.org/10.1182/blood.V126.23.3862.3862

Published: 2015

Journal Articles

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Blood (2015) 126 (23): 3736.

https://doi.org/10.1182/blood.V126.23.3736.3736

Published: 2015

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation

Anant Gokarn, MD, Vikram Gota, MDPGDCT, Gautam Goyal, MDDM, Alok Gupta, MD, Sachin Punatar, MD DM, Pravin Patil, MSc, Krunal Kavathiya, MPharm, Kamal Pathak, Murari Gujjar, Libin Mathew, Bhausaheb Bagal, MD DM., Sadhana Kannan, MSc, Navin Khattry, MDDM

Blood (2014) 124 (21): 2467.

https://doi.org/10.1182/blood.V124.21.2467.2467

Published: 2014

Journal Articles

Excess Late Gastrointestinal Toxicity Associated with Leam Conditioning Compared to BEAM for Autologous Stem Cell Transplantation in Lymphoma, a Single Institution Experience

Jaimal Kothari, FRCPath, Michael Foley, MBBS, Karl S Peggs, Kirsty Thomson, Emma Morris, FRCPath, Kirit M Ardeshna, MD FRCPath, Andres E. Virchis, FRCPath, David C Linch, FMedSci, Jonathan Lambert, FRCPath

Blood (2014) 124 (21): 5898.

https://doi.org/10.1182/blood.V124.21.5898.5898

Published: 2014

Journal Articles

Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi

Francesco Merli, MD, Stefano Luminari, MD, Caterina Mammi, PhD, Nicola Cascavilla, MD, Alessia Bari, MD, Caterina Stelitano, MD, Renato Scalone, MD, Luca Baldini, Prof, Francesco Angrilli, MD, Giuseppe Polimeno, MD, Paolo G Gobbi, Prof, Giulia Cervetti, MD, Fiorella Ilariucci, MD, Alessia Ruffini, Luigi Marcheselli, Massimo Federico, MD

Blood (2014) 124 (21): 499.

https://doi.org/10.1182/blood.V124.21.499.499

Published: 2014

Journal Articles

LACE - an Effective Conditioning Regimen for Lymphoma Patients Undergoing Autologous Transplant- Analysis of Outcomes and Prognostic Factors

Deepan Rajamanickam, MD, Anant Gokarn, MD, Alok Gupta, MD, Sachin Punatar, MD DM, Ravi Thippeswamy, MD DM, Bhausaheb Bagal, MD DM., Libin Mathew, Sadhana Kannan, MSc, Venkatesh Rangarajan, Navin Khattry, MDDM

Blood (2014) 124 (21): 3979.

https://doi.org/10.1182/blood.V124.21.3979.3979

Published: 2014

Journal Articles

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Anastasia Constantinidou, Caroline Ebdon, Kabir Mohammed, Mark Ethell, MD, Ian Chau, MD, David Cunningham, FMedSci, Michael Potter, PhD, Bhupinder Sharma, MD

Blood (2014) 124 (21): 3971.

https://doi.org/10.1182/blood.V124.21.3971.3971

Published: 2014

Journal Articles

Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥ 60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial

Blood (2013) 122 (21): 2691.

https://doi.org/10.1182/blood.V122.21.2691.2691

Published: 2013

Journal Articles

Safety and Efficacy Of Lomustine (CCNU) Substituting Carmustine (BCNU) In Conditioning For Autologous Haematopoietic Stem Cell Transplantation In Lymphoma. A Retrospective Analysis Of Two Patient Cohorts Over a Ten Year Period

Sven Armin Sommerfeld, MRCP,, Samar Kulkarni, MD, MRCP, FRCPath, David Kaye, Adrian Bloor, PhD, FRCP, FRCPath

Blood (2013) 122 (21): 2127.

https://doi.org/10.1182/blood.V122.21.2127.2127

Published: 2013

Journal Articles

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Pieternella J Lugtenburg, MD, PhD, Josée M Zijlstra, MD, PhD, Jeanette K Doorduijn, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD, PhD, Mels Hoogendoorn, MD, PhD, Henriette W Berenschot, MD, PhD, Aart Beeker, MD, Fransje A Valster, MD, Harry C Schouten, MD, PhD, Marleen Luten, MSc, Dana A Chitu, Rolf E Brouwer, MD, PhD, Gustaaf W van Imhoff, MD, PhD

Blood (2012) 120 (21): 2729.

https://doi.org/10.1182/blood.V120.21.2729.2729

Published: 2012

Journal Articles

Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation

Jiri Pavlu, Katayoun Rezvani, Bhuvan Kishore, Rifca Le Dieu, Joydeep Chakrabartty, Aristeidis Chaidos, Edward J Kanfer, Anastasios Karadimitris, Donald H MacDonald, David Marin, Dragana Milojkovic, MD, Farah O'Boyle, Amin Rahemtulla, David Slade, John M Goldman, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Richard M Szydlo

Blood (2011) 118 (21): 1945.

https://doi.org/10.1182/blood.V118.21.1945.1945

Published: 2011

Journal Articles

Comparison of Toxicity and Outcomes of BCNU-Containing Conditioning Regimens Vs LACE in Lymphoma Transplants: A Retrospective Multicenter Analysis

Navin Khattry, MD, DM, Reetu Jain, MD, Ravi Thippeswamy, MD, Adwaita Gore, DNB, Bharat Bhosale, MD, Nandish Jeevangi, MD, DM, Sadhana Kannan, MSc, Amit Joshi, MD, DM, Reena Nair, MD, Tapan Saikia, MD

Blood (2011) 118 (21): 2023.

https://doi.org/10.1182/blood.V118.21.2023.2023

Published: 2011

Journal Articles

Immuno-Chemotherapy with Rituximab, Methotrexate, Lomustine, and Procarbazine for the Treatment of Primary CNS Lymphoma in Patients >65 Years.

Kristina Fritsch, Benjamin Kasenda, Anna Markert, Jürgen Finke, Gerald Illerhaus

Blood (2009) 114 (22): 3712.

https://doi.org/10.1182/blood.V114.22.3712.3712

Published: 2009

Journal Articles

Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group

Blood (2008) 112 (11): 761.

https://doi.org/10.1182/blood.V112.11.761.761

Published: 2008

Journal Articles

Outcome of Refractory or Relapsed Patients after Front-Line Treatment for Hodgkin Lymphoma (HL): Experience of a Single Institution

Francesca Fioritoni, MD, Francesco Angrilli, MD, Simona Falorio, MD, Stella Santarone, MD, Giuseppe Fioritoni

Blood (2008) 112 (11): 4959.

https://doi.org/10.1182/blood.V112.11.4959.4959

Published: 2008

NARROW

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation

Excess Late Gastrointestinal Toxicity Associated with Leam Conditioning Compared to BEAM for Autologous Stem Cell Transplantation in Lymphoma, a Single Institution Experience

Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi

LACE - an Effective Conditioning Regimen for Lymphoma Patients Undergoing Autologous Transplant- Analysis of Outcomes and Prognostic Factors

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥ 60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial

Safety and Efficacy Of Lomustine (CCNU) Substituting Carmustine (BCNU) In Conditioning For Autologous Haematopoietic Stem Cell Transplantation In Lymphoma. A Retrospective Analysis Of Two Patient Cohorts Over a Ten Year Period

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation

Comparison of Toxicity and Outcomes of BCNU-Containing Conditioning Regimens Vs LACE in Lymphoma Transplants: A Retrospective Multicenter Analysis

Immuno-Chemotherapy with Rituximab, Methotrexate, Lomustine, and Procarbazine for the Treatment of Primary CNS Lymphoma in Patients >65 Years.

Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group

Outcome of Refractory or Relapsed Patients after Front-Line Treatment for Hodgkin Lymphoma (HL): Experience of a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only